International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 103-107
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
HEPATITIS B AND C SEROPREVALENCE IN CANCER PATIENTS: A CASE CONTROL STUDY
Güngör UTKAN1, Alpay AZAP2, Sadık MUALLAOĞLU1, Saadet TOKLUOĞLU1, Ayşe G. DURNALI1, Ülkü Y. ARSLAN1, Murat KOÇER1, Gökhan ÇELENKOĞLU1, Hakan AKBULUT3, Necati ALKIŞ1
1Ankara Onkoloji Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği, ANKARA
2Ankara Üniversitesi Tıp Fakültesi Klinik Bakteriyoloji ve İnfeksiyon Hastalıkları Bilim Dalı, ANKARA
3Ankara Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, ANKARA
Keywords: Hepatitis carrier state, Patient with cancer
During the diagnosis and treatment, patients with cancer may either become hepatitis carrier due to one or more reasons, or subject to the risk of hepatitis reactivation as a result of immunosuppressive treatment. This study aims to determine seroprevalence of Hepatitis B (HBV) or Hepatitis C (HCV) in adult patients with cancer, and compare them with patients who were admitted to hospital for non-cancer reasons. This study includes five-hundred patients who have been recently diagnosed with cancer (Group A) and five-hundred patients who were admitted to hospital for other reasons except for cancer (Group B). In Group A, prevalence of HBs Ag, Anti-HBs (AHBs) and Anti-HCV (AHCV) was measured as %4.8, %14, %2.8 respectively while the same rates were measured as %1.2, %42.4, %1.4 in the Group B. When the Group A was compared with the Group B, hepatitis carrier state (HBV or HCV) and HBs carrier state were more common in patients with cancer while a meaningful difference was not seen in regard to HCV. The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.
Güngör UTKAN1, Alpay AZAP2, Sadık MUALLAOĞLU1, Saadet TOKLUOĞLU1, Ayşe G. DURNALI1, Ülkü Y. ARSLAN1, Murat KOÇER1, Gökhan ÇELENKOĞLU1, Hakan AKBULUT3, Necati ALKIŞ1
1Ankara Onkoloji Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği, ANKARA
2Ankara Üniversitesi Tıp Fakültesi Klinik Bakteriyoloji ve İnfeksiyon Hastalıkları Bilim Dalı, ANKARA
3Ankara Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, ANKARA
Keywords: Hepatitis carrier state, Patient with cancer
During the diagnosis and treatment, patients with cancer may either become hepatitis carrier due to one or more reasons, or subject to the risk of hepatitis reactivation as a result of immunosuppressive treatment. This study aims to determine seroprevalence of Hepatitis B (HBV) or Hepatitis C (HCV) in adult patients with cancer, and compare them with patients who were admitted to hospital for non-cancer reasons. This study includes five-hundred patients who have been recently diagnosed with cancer (Group A) and five-hundred patients who were admitted to hospital for other reasons except for cancer (Group B). In Group A, prevalence of HBs Ag, Anti-HBs (AHBs) and Anti-HCV (AHCV) was measured as %4.8, %14, %2.8 respectively while the same rates were measured as %1.2, %42.4, %1.4 in the Group B. When the Group A was compared with the Group B, hepatitis carrier state (HBV or HCV) and HBs carrier state were more common in patients with cancer while a meaningful difference was not seen in regard to HCV. The difference seen in patients with cancer highlights importance of screening for pre-treatment hepatitis markers in this patient group.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |